Ae Ri Ahn

Ae Ri Ahn

Auto-generated profile, based on publicly available information

Ae Ri Ahn

Departments of Pathology and Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, 20 Geonji-ro, Deokjin-gu, Jeonju City, Jeollabuk-Do 54907, Republic of Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2019 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
AAAe Ri An
Ae Ri An
Kyoung Min KimKyoung Min Kim
Kyoung Min Kim
HPHo Sung Park
Ho Sung Park
Kyu JangKyu Jang
Kyu Jang
WMWoo Sung Moon
Woo Sung Moon
MCMyoung Ja Chung
Myoung Ja Chung
Exposure to cigarette smoking (CS) is a major risk factor for the development of lung cancer. CS is known to cause oxidative DNA damage and mutation of tumor-related genes, and these factors are involved in carcinogenesis. 8-Hydroxydeoxyguanosine (8-OHdG) is considered to be a reliable biomarker for oxidative DNA damage. Increased levels of 8-OHdG are associated with a number of pathological conditions, including cancer. There are no reports on the expression of 8-OHdG by immunohistochemistry in non-small cell lung cancer (NSCLC). We investigated the expression of 8-OHdG and p53 in 203 NSCLC tissues using immunohistochemistry and correlated it with clinicopathological features including smoking. The expression of 8-OHdG was observed in 83.3% of NSCLC. It was significantly correlated with a low T category, negative lymph node status, never-smoker, and longer overall survival (p < .05) by univariate analysis. But multivariate analysis revealed that 8-OHdG was not an independent prognostic factor for overall survival in NSCLC patients. The aberrant expression of p53 significantly correlated with smoking, male, squamous cell carcinoma, and Ki-67 positivity (p < .05). The expression of 8-OHdG was associated with good prognostic factors. It was positively correlated with never-smokers in NSCLC, suggesting that oxidative damage of DNA cannot be explained by smoking alone and may depend on complex control mechanisms.

15 March 2020 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
MKMyoung Jae Kang
Myoung Jae Kang
AAAe Ri An
Ae Ri An
MCMyoung Ja Chung
Myoung Ja Chung
Kyoung Min KimKyoung Min Kim
Kyoung Min Kim

9 January 2021 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
Kyoung Min KimKyoung Min Kim
Kyoung Min Kim
UHUsama Hussein
Usama Hussein
See-Hyoung ParkSee-Hyoung Park
See-Hyoung Park
YMYoung Jae Moon
Young Jae Moon
ZZZhongkai Zhang
Zhongkai Zhang
Kyu JangKyu Jang
Kyu Jang
Background: IL4Rα and IL13Rα1 are constituents of the type II IL4 receptor. Recently, IL4Rα and IL13Rα1 were reported to have roles in cancer progression and suggested as potential prognostic markers. However, studies on IL4Rα and IL13Rα1 in soft-tissue sarcomas have been limited. Methods: This study investigated the immunohistochemical expression of IL4Rα and IL13Rα1 in 89 soft-tissue sarcomas of the extremities, superficial trunk, and retroperitoneum. Immunohistochemical staining for IL4Rα and IL13Rα1 were scored according to a combination of staining intensity and staining area in tissue microarray samples. Positivity for the immunohistochemical expression of IL4Rα and IL13Rα1 were determined using receiver operating curve analysis. Statistical analysis was performed using regression analysis and a chi-square test. Results: In human soft-tissue sarcomas, immunohistochemical expression of IL4Rα was significantly associated with IL13Rα1 expression. Nuclear and cytoplasmic expression of IL4Rα and IL13Rα1 were significantly associated with shorter survival of soft-tissue sarcoma patients in univariate analysis. Multivariate analysis indicated that nuclear expression of IL4Rα and IL13Rα1 were independent indicators of shorter overall survival (IL4Rα; p = 0.002, IL13Rα1; p = 0.016) and relapse-free survival (IL4Rα; p = 0.022, IL13Rα1; p < 0.001) of soft-tissue sarcoma patients. Moreover, the co-expression pattern of nuclear IL4Rα and IL13Rα1 was an independent indicator of shorter survival of soft-tissue sarcoma patients (overall survival; overall p < 0.001, relapse-free survival; overall p < 0.001). Conclusions: This study suggests IL4Rα and IL13Rα1 are associated with the progression of soft-tissue sarcoma, and the expression of IL4Rα and IL13Rα1 might be novel prognostic indicators of soft-tissue sarcoma patients.

20 August 2021 in Pathology International
Verified
Journal Article
Closed access
PDF file
AAAe Ri Ahn
Ae Ri Ahn
JSJi Soo Song
Ji Soo Song
JYJae Do Yang
Jae Do Yang
WMWoo Sung Moon
Woo Sung Moon

15 March 2020 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
AAAe Ri An
Ae Ri An
Kyoung Min KimKyoung Min Kim
Kyoung Min Kim
JKjong hun Kim
jong hun Kim
GJGong Yong Jin
Gong Yong Jin
YCYoung Hoon Choe
Young Hoon Choe
MCMyoung Ja Chung
Myoung Ja Chung

20 April 2023 in Archives of Craniofacial Surgery
Verified
Journal Article
Open access
PDF file
YCYoon Kyu Chung
Yoon Kyu Chung
MKMin-Seok Kim
Min-Seok Kim
JSJin Yong Shin
Jin Yong Shin
NLNae-Ho Lee
Nae-Ho Lee
AAAe Ri An
Ae Ri An
SRSi-Gyun Roh
Si-Gyun Roh
Blue nevi, which are characterized by collections of pigment-producing melanocytes in the dermis, have a variety of clinicopathological characteristics. Plaque-type blue nevus (PTBN) is a variant of blue nevi. PTBN presents at birth or arises in early childhood, and it shows a combination of the features found in common blue nevus and cellular blue nevus. It is typically found on the dorsal surface of the hands and feet or on the head and neck, and it is usually benign and stable over time. However, reports have occasionally described malignant melanomas developing in or associated with a PTBN. Malignant blue nevi are most commonly found on the scalp. We report the case of an 88-year-old woman with a malignant melanoma associated with a PTBN of the cheek.